# Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy

> **NIH NIH K24** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2023 · $120,424

## Abstract

Abstract
I have built a successful patient oriented research program focused on pharmacogenomics,
pharmacoepidemiology, and chronic disease epidemiology with a focus on cardiovascular diseases. My
research goal is to elucidate the role of clinical, environmental and genetic factors on variability in
cardiovascular disease risk and response to medications and to use this information to tailor treatments,
especially in patients with multiple comorbidities.
The proposed award would enable me to continue mentoring while expanding my research program
specifically incorporating implementation science tools to address key translational knowledge gaps. The
new research proposed herein is builds on ongoing work to create unique and much needed patient
oriented research (POR) training opportunities in cardiovascular pharmacotherapeutics and improvement in
risk prediction by incorporating genomic information. My NIH grants along with the four new projects will
form the basis for the mentee (MD, Pharm.D, and PhD) training. Mentorship aims expand the POR training
opportunities for trainees. Mentees will lead the new projects, develop skills related to discovery and
implementation, conduct analysis and publish original research. They will leverage this to propose new
research as part of their NIH- K23 applications.
PROJECT1 will elucidate the differential effect of sex and age on gene-hemorrhage association among
anticoagulant users. PROJECT 2 will evaluate the influence of pharmacogenetic variants on Apixaban and
Rivaroxaban pharmacokinetics and pharmacodynamics. PROJECT 3 will evaluate the performance of
bleeding risk scores and the integration of genetics in risk prediction among patients with acute coronary
syndrome (ACS) undergoing percutaneous coronary intervention (PCI). PROJECT 4 will evaluate the
influence of heart failure on outcomes among patients with ACS undergoing PCI.
In the supportive and collaborative environment of UAB, this award will ensure that I continue to grow my
research program expand to include hybrid implementation-effectiveness designs and build capacity in POR
by mentoring junior investigators to build their own careers. The breadth and depth of the multiple NIH-
funded institutional training programs, UAB’s CTSA and her leadership in UAB’s Translational
Pharmacogenomics and Precision Medicine Institute will provide the resources and the foundation to
advance discovery and implementation efforts to enable translation of research discoveries into clinical
care.

## Key facts

- **NIH application ID:** 10691265
- **Project number:** 5K24HL133373-08
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** NITA A LIMDI
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $120,424
- **Award type:** 5
- **Project period:** 2016-08-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10691265

## Citation

> US National Institutes of Health, RePORTER application 10691265, Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy (5K24HL133373-08). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10691265. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*